James L, Georgopoulos A
Vaccines (Basel). 2025; 13(1).
PMID: 39852867
PMC: 11768865.
DOI: 10.3390/vaccines13010088.
James L, Carpenter A, Engdahl B, Johnson R, Lewis S, Georgopoulos A
Vaccines (Basel). 2024; 12(6).
PMID: 38932342
PMC: 11209475.
DOI: 10.3390/vaccines12060613.
Georgopoulos A, James L
Vaccines (Basel). 2024; 12(2).
PMID: 38400142
PMC: 10892718.
DOI: 10.3390/vaccines12020159.
Brown K, Zanos P, Powels C, Fix C, Michaelides M, Pereira E
Neuropharmacology. 2022; 225:109403.
PMID: 36565852
PMC: 9867909.
DOI: 10.1016/j.neuropharm.2022.109403.
Cohen-Gihon I, Israeli O, Beth-Din A, Levy H, Cohen O, Shafferman A
Genome Announc. 2014; 2(1).
PMID: 24526646
PMC: 3924378.
DOI: 10.1128/genomeA.00075-14.
IgG subclass and heavy chain domains contribute to binding and protection by mAbs to the poly γ-D-glutamic acid capsular antigen of Bacillus anthracis.
Hovenden M, Hubbard M, AuCoin D, Thorkildson P, Reed D, Welch W
PLoS Pathog. 2013; 9(4):e1003306.
PMID: 23637599
PMC: 3630167.
DOI: 10.1371/journal.ppat.1003306.
Mechanism of HERG potassium channel inhibition by tetra-n-octylammonium bromide and benzethonium chloride.
Long Y, Lin Z, Xia M, Zheng W, Li Z
Toxicol Appl Pharmacol. 2013; 267(2):155-66.
PMID: 23313619
PMC: 4884629.
DOI: 10.1016/j.taap.2012.12.021.
Occurrence, recognition, and reversion of spontaneous, sporulation-deficient Bacillus anthracis mutants that arise during laboratory culture.
Sastalla I, Leppla S
Microbes Infect. 2011; 14(5):387-91.
PMID: 22166343
PMC: 3306515.
DOI: 10.1016/j.micinf.2011.11.009.
Vaccination of rhesus macaques with the anthrax vaccine adsorbed vaccine produces a serum antibody response that effectively neutralizes receptor-bound protective antigen in vitro.
Clement K, Rudge Jr T, Mayfield H, Carlton L, Hester A, Niemuth N
Clin Vaccine Immunol. 2010; 17(11):1753-62.
PMID: 20739500
PMC: 2976102.
DOI: 10.1128/CVI.00174-10.
Anthrax LFn-PA Hybrid Antigens: Biochemistry, Immunogenicity, and Protection Against Lethal Ames Spore Challenge in Rabbits.
Li Q, Peachman K, Sower L, Leppla S, Shivachandra S, Matyas G
Open Vaccine J. 2011; 2:92-99.
PMID: 20390054
PMC: 2853182.
DOI: 10.2174/1875035400902010092.
Sequential B-cell epitopes of Bacillus anthracis lethal factor bind lethal toxin-neutralizing antibodies.
Nguyen M, Crowe S, Kurella S, Teryzan S, Cao B, Ballard J
Infect Immun. 2008; 77(1):162-9.
PMID: 18981257
PMC: 2612257.
DOI: 10.1128/IAI.00788-08.
Toxicity of anthrax toxin is influenced by receptor expression.
Taft S, Weiss A
Clin Vaccine Immunol. 2008; 15(9):1330-6.
PMID: 18596206
PMC: 2546661.
DOI: 10.1128/CVI.00103-08.
Genetic medicine strategies to protect against bioterrorism.
Boyer J, Crystal R
Trans Am Clin Climatol Assoc. 2008; 117:297-310.
PMID: 18528482
PMC: 1500914.
Interlaboratory comparison of results of an anthrax lethal toxin neutralization assay for assessment of functional antibodies in multiple species.
Omland K, Brys A, Lansky D, Clement K, Lynn F
Clin Vaccine Immunol. 2008; 15(6):946-53.
PMID: 18417668
PMC: 2446612.
DOI: 10.1128/CVI.00003-08.
Neutralizing activity of vaccine-induced antibodies to two Bacillus anthracis toxin components, lethal factor and edema factor.
Taft S, Weiss A
Clin Vaccine Immunol. 2007; 15(1):71-5.
PMID: 18032590
PMC: 2223847.
DOI: 10.1128/CVI.00321-07.
The Gordon Wilson lecture: using genetic medicine to regenerate diseased organs and protect against the hostile environment.
OConnor T, Crystal R
Trans Am Clin Climatol Assoc. 2006; 115:163-83.
PMID: 17060966
PMC: 2263768.
Nasal immunization with anthrax protective antigen protein adjuvanted with polyriboinosinic-polyribocytidylic acid induced strong mucosal and systemic immunities.
Sloat B, Cui Z
Pharm Res. 2006; 23(6):1217-26.
PMID: 16718616
DOI: 10.1007/s11095-006-0206-9.
Strong mucosal and systemic immunities induced by nasal immunization with anthrax protective antigen protein incorporated in liposome-protamine-DNA particles.
Sloat B, Cui Z
Pharm Res. 2005; 23(2):262-9.
PMID: 16319999
DOI: 10.1007/s11095-005-9078-7.
Human anti-anthrax protective antigen neutralizing monoclonal antibodies derived from donors vaccinated with anthrax vaccine adsorbed.
Sawada-Hirai R, Jiang I, Wang F, Sun S, Nedellec R, Ruther P
J Immune Based Ther Vaccines. 2004; 2(1):5.
PMID: 15140257
PMC: 420254.
DOI: 10.1186/1476-8518-2-5.
Use of a promoter trap system in Bacillus anthracis and Bacillus subtilis for the development of recombinant protective antigen-based vaccines.
Gat O, Inbar I, Aloni-Grinstein R, Zahavy E, Kronman C, Mendelson I
Infect Immun. 2003; 71(2):801-13.
PMID: 12540560
PMC: 145393.
DOI: 10.1128/IAI.71.2.801-813.2003.